MacroGenics Inc (NASDAQ: MGNX) reported a diluted earnings per share (EPS) of $(0.31) for the quarter ended June 30, 2026, missing the analyst estimate of $0.02. The company also disclosed an adjusted EPS of $(0.27), which missed the analyst consensus estimate of $(0.13) by 107.69 percent. This represents a 52.63 percent increase in losses compared to $(0.57) per share in the same period last year.

Total revenue for the quarter stood at $32.832 million, significantly below the $67.456 million estimate, marking a 51.33 percent miss. Despite this shortfall, sales rose 47.62 percent from $22.241 million in the same period last year.

Despite the miss on per-share metrics and top-line forecasts, the company reported a net income of $19.5 million, compared to a net loss of $36.3 million in the same period last year. This turnaround was driven entirely by non-operational factors, specifically an $89.2 million gain from discontinued operations following the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals.

Financial Performance

Total revenue reached $32.8 million (rounded from $32.832 million), up significantly from $6.9 million in Q2 2025. This increase was largely attributable to a $24.5 million regulatory milestone payment earned from Sanofi regarding the U.S. approval of TZIELD. Collaborative and other agreement revenues stood at $25.5 million, while royalty revenue was $7.3 million.

Despite the top-line growth, MacroGenics recorded a loss from operations of $13.9 million in Q2 2026, compared to $43.2 million in the prior year. Research and development expenses decreased slightly to $38.8 million from $40.8 million, reflecting lower costs for lorigerlimab and discontinued programs, partially offset by increased trial costs for MGC026 and MGC028. General and administrative expenses fell to $7.9 million from $9.3 million due to reduced personnel-related costs.

The company also recognized a $52.8 million non-cash loss on the extinguishment of the ZYNYZ royalty monetization liability. Interest and other expense was $4.4 million, while interest and other income totaled $1.4 million.

What the Numbers Show

The reported net income masks a significant operational deficit. The $19.5 million net profit is derived from adding the $89.2 million gain from discontinued operations to the $69.6 million net loss from continuing operations. Consequently, the core business continues to burn cash, with operating losses widening when adjusted for the one-time royalty extinguishment loss. Investors should note that the pro forma cash position of $327 million includes proceeds from the Bora transaction ($119.6 million), the pending Sanofi milestone ($24.5 million), and a recent $10.0 million milestone from Gilead, none of which were in the cash balance as of June 30.

Balance Sheet and Cash Position

Cash, cash equivalents, and marketable securities stood at $173.3 million as of June 30, 2026, down from $189.9 million at the end of December 2025. This decline occurred despite receiving $60.0 million from Sagard Healthcare Partners related to ZYNYZ royalties.

Subsequent to the quarter-end, the company received $119.6 million from the Bora sale and $10.0 million from Gilead. Including these post-period inflows and the expected Sanofi milestone, the pro forma cash balance is $327 million. Management stated this position supports a cash runway through 2028.

Pipeline Progress

MacroGenics advanced several key pipeline assets during the quarter:

• MGC026: The dose-escalation phase of the Phase 1 study for this B7-H3 ADC is complete. The squamous cell carcinoma of the head and neck cohort met response thresholds to advance to Stage 2. Interim results will be presented at ESMO 2026.
• MGC028: Dose escalation for this ADAM9-targeting ADC is ongoing, with preliminary results expected in late 2026.
• MGC030: The IND application for this undisclosed antigen ADC was cleared ahead of schedule, with first patient dosing planned for Q3 2026.
• Lorigerlimab: The Phase 2 LINNET study continues, with interim data accepted for ESMO 2026 presentation. Enrollment of additional clear cell gynecologic cancer patients is underway.

MacroGenics, Inc. (NASDAQ: MGNX) secured a $10 million payment after Gilead Sciences, Inc. exercised its option to exclusively license a preclinical bispecific program under their 2022 collaboration agreement. This transaction validates the commercial potential of MacroGenics’ early-stage pipeline assets and reinforces the strategic value of its ongoing partnership with Gilead. For investors, this milestone provides immediate cash inflow while preserving significant upside potential through future development and regulatory achievements.

The licensed program incorporates MacroGenics’ proprietary TRIDENT platform and is directed against two undisclosed targets for the treatment of solid tumors. This option exercise occurs within the framework of the companies’ 2022 collaboration agreement, which currently advances three distinct programs. These include MGD024, a clinical-stage CD123 × CD3 bispecific DART molecule, alongside two preclinical bispecific programs, one of which was just licensed by Gilead.

Collaboration Structure

The financial terms of the 2022 agreement provide MacroGenics with substantial long-term revenue potential beyond the initial $10 million upfront payment. The company remains eligible to receive up to approximately $1.6 billion in additional payments tied to development, regulatory, and commercial milestones. Furthermore, MacroGenics will earn royalties on worldwide net sales of any products resulting from the collaborative programs. This structure aligns incentives for both parties to advance the pipeline efficiently while ensuring MacroGenics participates in the commercial success of the licensed assets.

Strategic Implications

The exercise of this option highlights the strategic importance of MacroGenics’ antibody-based technology platforms. By licensing a preclinical asset, Gilead demonstrates confidence in the TRIDENT platform’s ability to generate viable candidates for solid tumors, a high-unmet-need area in oncology. This deal reduces development risk for MacroGenics by transferring resources to a larger partner while retaining significant upside through milestone payments and royalties. The $10 million injection supports continued operations and research into remaining pipeline candidates, including the clinical-stage MGD024 program.